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Abstract. 
 
During differentiation, skeletal muscle cells 
withdraw from the cell cycle and fuse into multinucle-
ated myotubes. Unlike quiescent cells, however, these 
cells cannot be induced to reenter S phase by means of 
growth factor stimulation. The studies reported here 
document that both the retinoblastoma protein (Rb) 
and the cyclin-dependent kinase (cdk) inhibitor p21 
contribute to this unresponsiveness. We show that the 
inactivation of Rb and p21 through the binding of the 
adenovirus E1A protein leads to the induction of DNA 
replication in differentiated muscle cells. Moreover, in-
activation of p21 by E1A results in the restoration of 
cyclin E–cdk2 activity, a kinase made nonfunctional by 
the binding of p21 and whose protein levels in differen-
tiated muscle cells is relatively low in amount. We also 
show that restoration of kinase activity leads to the 
phosphorylation of Rb but that this in itself is not sufﬁ-
cient for allowing differentiated muscle cells to reenter 
the cell cycle. All the results obtained are consistent 
with the fact that Rb is functioning downstream of p21 
and that the activities of these two proteins may be 
linked in sustaining the postmitotic state.
Key words: C2C12 cells • E1A • cell cycle • p21 • 
DNA replication
 
Introduction
 
The process of skeletal muscle differentiation is distin-
guished by at least three orderly events: permanent with-
drawal from the cell cycle, phenotypic differentiation, and
the fusion of cells into multinucleated myotubes (Lassar et
al., 1994). The regulatory factors required for these biolog-
ical processes include the four transcription factors MyoD,
myogenin, Myf-5, and MRF4 (Weintraub, 1993). Each of
these myogenic proteins can induce myogenesis in a vari-
ety of nonmuscle cell types, and as a family, they act in
concert with the MEF2 family of transcription factors to
activate muscle-specific genes, among which are myosin
heavy chain (MHC)
 
1
 
 and muscle creatine kinase (Lassar et
al., 1994; Olson et al., 1996). As a rule, most myoblasts in
culture express MyoD or Myf5 (Weintraub, 1993), and it is
only after these cells are deprived of serum do these fac-
tors then begin to initiate temporal events (Andres and
Walsh, 1996), which ultimately end in the formation of
postmitotic myotubes. Therefore, it would appear that
proliferating myoblasts have operative mechanisms that
continually restrain the activity of these myogenic regula-
tors. Considerable effort has been directed at defining the
nature of this restraint, and it now appears that cyclin D1,
the partner of cyclin-dependent kinase (cdk)4/6, may be
important in maintaining MyoD in a functionally inactive
state (Skapek et al., 1995, 1996). Indeed, forced expression
of cdk inhibitors such as p16 or p21 in proliferating myo-
blasts apparently results in the activation of MyoD func-
tion (Skapek et al., 1995), suggesting, therefore, that phos-
phorylation may be important to its activity.
In order for skeletal muscle cells to terminally differen-
tiate in vivo or in vitro, they must first irreversibly with-
draw from the cell cycle (Lassar et al., 1994), and in cul-
tured cells this process usually occurs in mid–late G1
(Thorburn et al., 1993). The coupling of cell cycle arrest to
myogenic differentiation may be based on the induction of
the cdk inhibitors p18 and p21 (Guo et al., 1995; Halevy et
al., 1995; Parker et al., 1995; Missero et al., 1996; Franklin
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and Xiong, 1996). Historically, p21 is perhaps best known
for its importance to several processes requiring cell cycle
arrest, particularly in cells having sustained DNA damage
by genotoxic agents (Sherr and Roberts, 1995). Evidence
indicates that p21 may also be important for maintaining
cell cycle arrest in differentiated muscle cells, since its ex-
pression occurs subsequently to that of myogenin, an early
muscle differentiation marker (Andres and Walsh, 1996).
In most cases, p21 is upregulated by the tumor suppressor
protein p53, but in cultured myoblasts its induction ap-
pears to be mediated by MyoD (Halevy et al., 1995; Otten
et al., 1997). In fact, forced expression of MyoD in non-
muscle cells causes p21 to accumulate in relatively high
amounts (Halevy et al., 1995).
The result of increased levels of p21 protein in differen-
tiated muscle cells is clearly seen by a decrease in cdk2 ac-
tivity (Guo et al., 1995; Missero et al., 1995). In proliferat-
ing cells, p21 preferably inhibits cdks that are involved in
promoting cells into S phase and in augmenting the phos-
phorylation of the retinoblastoma protein (Rb) (Sherr,
1994). In the early stages of the myogenic program, Rb
assumes a hypophosphorylated or active form, and evi-
dence indicates that p21 may be taking an active role in
this process. Indeed, neither p21 nor p16 is able to prevent
Rb-negative myocytes from entering S phase when ectopi-
cally expressed in these cells (Novitch et al., 1996). Earlier
studies cast Rb in the role of regulating the transition be-
tween cell cycle progression and muscle cell differentia-
tion (Lassar et al., 1994). However, it now appears that Rb
may be more connected to pathways that prohibit the rep-
lication of DNA in differentiated muscle cells. For exam-
ple, differentiated myotubes with a functionally inactive
Rb are fully capable of reentering S phase (Gu et al.,
1993), and although Rb-deficient myocytes can success-
fully differentiate in culture, they are powerless in pre-
venting DNA synthesis when stimulated with serum
(Schneider et al., 1994; Novitch et al., 1996). One of the
major activities of Rb in undifferentiated cells is to nega-
tively regulate the E2F family of transcriptional factors,
especially E2F1 that prefers to activate S phase genes
(Dyson, 1998). However, although this particular function
of Rb is presumably operative in proliferating myoblasts,
it may not be in differentiated cells, since these cells ex-
press very little, if any E2F1 (Wang et al., 1995; Tiainen et
al., 1996). Moreover, it is intriguing that forced expression
of E2F1 in differentiated muscle cells does not result in
the reactivation of DNA synthesis (Wang et al., 1995;
Tiainen et al., 1996), whereas in quiescent cells it does
(Kowalik et al., 1995). This may be attributed to the fact
that although exogenous E2F1 increases the levels of cy-
clin E in differentiated muscle cells, the kinase activity of
cdk2 remains unaffected (Pajalunga et al., 1999). Further-
more, unlike E2F1, the E2F4 protein is produced in dif-
ferentiated muscle cells and is found predominantly in as-
sociation with p130, an Rb family member. In fact, the
E2F4–p130 complex appears to be the most abundant
E2F–DNA binding species in these cells (Puri et al., 1997,
1998).
Such observations raise questions concerning the type of
mechanisms that prevent differentiated muscle cells from
reentering S phase, particularly since viral proteins such as
simian virus 40 (SV40) large T antigen and the viral onco-
protein E1A can act alone in inducing DNA synthesis in
these cells (Iujvidin et al., 1990; Gu et al., 1993; Crescenzi
et al., 1995). It would seem, therefore, that differentiated
muscle cells may be fully equipped to undergo DNA syn-
thesis, and because these viral proteins share the ability to
bind Rb (Herwig and Strauss, 1997), then conceivably, Rb
could be acting as a guard against the initiation of such a
process. However, since p21-negative mononucleated myo-
cytes can still synthesize their DNA after undergoing the
differentiation process (Andres and Walsh, 1996), it is pos-
sible that p21 may be involved in this activity as well. Thus,
given the likely importance of p21 and Rb in maintaining
the postmitotic state of differentiated muscle cells, we ana-
lyzed the effect of E1A on these proteins to further define
their role in preventing these cells from reentering S
phase. We find that E1A has the capacity to neutralize the
effect of p21 in differentiated muscle cells and that this ac-
tivity correlates with its ability to induce DNA synthesis in
these cells. Moreover, our data suggest that there may be a
link between p21 and Rb in maintaining the absence of
DNA replication in differentiated muscle cells and that
both proteins may be equally important to this activity.
 
Materials and Methods
 
Cell Culture, Transfections, and Monitoring of
DNA Synthesis
 
Monolayers of C2C12 (C2) mouse myoblasts (kindly provided by Nadia
Rosenthal, Massachusetts General Hospital, Boston, MA) were main-
tained in growth medium (GM) consisting of DME and 20% FBS. To pre-
pare differentiated myotubes, myoblasts were cultured in differentiating
medium (DM) (DME, 2% heat-inactivated horse serum, and 10 
 
m
 
g/ml of
insulin) for 12 h. Afterwards, cytosine arabinoside (10 
 
m
 
M) was added for
a period of 36 h to eliminate proliferating, nondifferentiating myoblasts
(Guo et al., 1995). As reported previously (Neville et al., 1997), this partic-
ular clone of C2 begins to fuse within 24 h when cultured under these con-
ditions. The extent of differentiation was routinely monitored by MHC
immunofluorescence (see below) and visual examination estimated 
 
.
 
95%
of the nuclei to be present in multinucleated cells. For transfection, differ-
entiated myotubes grown on acid-washed glass coverslips or 10-cm plates
were transfected with the appropriate plasmid by the Lipofectamine
PLUS (GIBCO BRL) method. The transfection efficiency under our con-
ditions was 
 
z
 
15–20%, as reported previously (Wolff et al., 1992). To mon-
itor for DNA synthesis, myotubes cultured on glass coverslips and trans-
fected with pCMV-E1A
 
12S
 
, pCMV-E1A.2-36, pCMV-E1A.928, or pCMV
(control vector) were labeled with 25 
 
m
 
M 5-bromodeoxyuridine (BrdU)
for 12 h, 24 h after transfection. Afterwards, the cells were fixed in 4%
paraformaldehyde and permeabilized in 0.5% Trition X-100 as described
previously (Cardoso et al., 1993). Primary antibodies used for immunoflu-
orescence were the mAb to E1A (M73) (Harlow et al., 1985), a gift from
E. Harlow (Massachusetts General Hospital, Boston, MA), and the anti-
BrdU mAb conjugated to FITC (Boehringer). The secondary antibody
for E1A staining was Texas red–conjugated rabbit anti–mouse IgG (Jack-
son Laboratory). Specimens for immunofluorescence were examined us-
ing a Nikon Optiphot-2 fluorescence microscope and then digitally cap-
tured (Oncor Video Imaging System).
 
Expression Plasmids and Purification of Protein
 
The mammalian expression vector pcDNA3 (Invitrogen) containing ei-
ther E1A
 
12S
 
, E1A.928, or E1A.2-36 downstream of the CMV promoter
was described previously (Lundblad et al., 1995; Mal et al., 1996). pGEM4
plasmids (Promega) containing the coding sequence of wild-type or mu-
tant E1As were kindly provided by P. Raychaudhuri (University of Illi-
nois, Chicago, IL) (Raychaudhuri et al., 1991). The plasmid expressing
glutathione 
 
S
 
-transferase (GST)-p21 and GST versions of p21 
 
D
 
1-37, p21
 
D
 
1-80, p21 
 
D
 
1-119, p21 
 
D
 
157-164, p21 
 
D
 
150-164, p21 
 
D
 
138-164, p21 
 
D
 
120-
164, p21 
 
D
 
87-164, p21 
 
D
 
72-164, and p21 
 
D
 
58-164 were cloned into pGEX- 
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KG (Poon and Hunter, 1998). Expression of GST-p21 fusion proteins was
performed in 
 
Escherichia coli
 
 strain BL21 (DE3). Induction of these pro-
teins by isopropyl-
 
b
 
-
 
D
 
-thiogalactopyranoside and their purification using
glutathione-Sepharose beads (Pharmacia) has been described previously
(Mal et al., 1996). Once purified, the GST fusion proteins were quanti-
tated by using the Bradford assay (Bio-Rad) and analyzed by SDS-PAGE
before use. An authentic E1A 243R amino acid as well as a mutant
E1A.928 protein produced and purified from bacteria was reported else-
where (Wang et al., 1992).
 
Cell Extractions
 
Myoblasts or myotubes were extracted for 1 h at 4
 
8
 
C in lysis buffer B con-
taining 50 mM Hepes, pH 7.0, 150 mM NaCl, 0.1% NP-40, 1 mM DTT,
1 mM EDTA, 10% glycerol, 5 mM NaF, 1 mM sodium orthovanadate, 5
mM Na-pyrophosphate, 5 
 
m
 
g/ml aprotinin, 2.5 
 
m
 
g/ml leupeptin, and 0.5
mM PMSF. Afterwards, extract in buffer B was passed 10 times through a
22-gauge needle and then centrifuged for the removal of cell debris.
 
Antibodies, Immunoblotting, and Immunoprecipitations
 
Anti–cyclin E (M20), anti-cdk2 (M2), anti-p21 (C19), anti-p18 (M-168),
and anti-Rb (C15) polyclonal antibodies were from Santa Cruz Biotech-
nology. Anti-cdk2 mouse mAb was from Transduction Laboratories. The
mAbs MF20 (Bader et al., 1982) and M73 (Harlow et al., 1985) were used
to identify MHC and the E1A protein, respectively. Anti-p27 was gener-
ously provided by J. Massague (Polyak et al., 1994). For immunoblot anal-
ysis, whole-cell extracts (50 
 
m
 
g) were separated on 7.5 or 12% SDS-poly-
acrylamide gels and transferred to polyvinylidene difluoride membrane.
The membranes were blocked in blocking buffer (4% dry milk, 0.1%
Tween 20, 1
 
3
 
 TBS) and incubated with primary antibodies in immuno-
blotting buffer (1
 
3 
 
TBS, 0.1% Tween 20, 1% BSA). Dilutions of primary
antibodies were according to the manufacturer’s instructions. After four
washes in immunoblot buffer, the blots were incubated with peroxidase-
coupled secondary antibodies and then developed by using the ECL
chemiluminescence reagent (Amersham Pharmacia Biotech). Lysis of
cells and immunoprecipitation conditions were described previously (Mal
et al., 1996). For determining the amount of p21 bound to E1A, 1.5 mg of
transfected cell lysate was immunoprecipitated with anti-E1A (M73) and
the precipitated products resolved on a 10% SDS-polyacrylamide gel.
Bound p21 was visualized by immunoblot analysis (described above) us-
ing antibodies against p21.
 
In Vitro Protein Interactions
 
Binding of equal molar amounts of GST fusion proteins to glutathione
agarose beads, incubation with purified bacterially produced E1A 243R
protein, and E1A detection by immunoblotting after the elution of beads
have been described previously (Lundblad et al., 1995; Mal et al., 1996).
Vectors (pGEM) containing the coding sequence of wild-type or mutant
E1As were subject to in vitro transcription/translation (Promega) to pro-
duce 
 
35
 
S-labeled proteins. Equal amounts of the labeled E1A proteins, as
judged by SDS-PAGE, were incubated with GST or GST-p21 as de-
scribed previously (Mal et al., 1996). GST and GST-p21 were captured by
glutathione-agarose beads, which were then washed accordingly. After-
wards, the beads were boiled in 2
 
3
 
 Laemmli buffer and the products were
then resolved on a 10% SDS-polyacrylamide gel. The [
 
35
 
S]methionine-
labeled proteins were analyzed by autoradiography.
 
Kinase Activity Assays
 
For restoration of kinase activity by purified E1A, whole cell extract (100
 
m
 
g) was incubated with or without wild-type or mutant E1A (100 ng) on
ice for 30 min. Afterwards, the mixtures were incubated at 30
 
8
 
C for 30
min. cdk2 was then recovered by immunoprecipitation and assayed for as-
sociated kinase H1 activity as described previously (Mal et al., 1996). In
brief, immune complexes of cdk2 were washed twice in buffer B contain-
ing 10% glycerol and twice with kinase buffer containing 20 mM Hepes,
pH 7.9, 1 mM DTT, 10 mM MgCl, and 10% glycerol. Afterwards, the
beads were resuspended in 20 
 
m
 
l kinase buffer containing histone H1 (0.2
 
m
 
g), 25 
 
m
 
M cold ATP, and 5 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP. After incubating for 30 min
at 30
 
8
 
C, the reactions were terminated by 2
 
3
 
 sample buffer. Phosphory-
lated products were analyzed on an 8% SDS-polyacrylamide gel and visu-
alized by autoradiography. Exposure time in all experiments was usually
 
,
 
30 min. To monitor for restoration of kinase activity in myotubes after
transfection with wild-type or mutant E1As, 100 
 
m
 
g of transfected whole
cell extract was immunoprecipitated with anti-cdk2. The recovered im-
mune complexes were then assayed for associated kinase activity as de-
scribed above. For the inhibitory reaction, purified E1A (200 ng) was in-
cubated for 30 min at 4
 
8
 
C in extracts of myotubes and recovered by
immunoprecipitation by anti-E1A (M73). Proteins released from the im-
mune complexes, as described previously (Mal et al., 1996), were mixed
with extracts (100 
 
m
 
g) of proliferating myoblasts and afterwards this mix-
ture was assayed for p21-associated histone H1 activity after immunopre-
cipitation.
 
Results
 
Correlation Kinetics of cdk2 Activity and Timing of p21 
Induction during Muscle Cell Differentiation
 
In general, cdk2 activity requires cyclin binding, and to be
fully effective, it needs to be phosphorylated by the cdk-
activating kinase (CAK) (Morgan, 1997). In proliferating
cells, cdk2 forms a complex with cyclin E near the G1–S
boundary, and throughout this interval, it ostensibly acts
at origins of replication to induce the initiation of DNA
synthesis (Ohtsubo et al., 1995; Mumberg et al., 1996). p21
is an important mediator of differentiative and/or antipro-
liferative signals, and as a rule, it inhibits cyclin–cdk2 com-
plexes that are important to the induction of DNA synthe-
sis (Harper et al., 1995). In differentiation, this is best
illustrated by the fact that myogenic cells devoid of p21
can now synthesize their DNA when restimulated by se-
rum (Andres and Walsh, 1996). Normally, differentiated
myotubes display high levels of p21 mRNA and protein
compared with proliferating myoblasts (Guo et al., 1995;
Halevy et al., 1995; Missero et al., 1995; Tiainen et al.,
1996). Moreover, p21 has also been shown to contribute to
the reduction of cdk activity in these cells (Jahn et al.,
1994; Guo et al., 1995), suggesting therefore that p21 may
be in control of inhibiting cdks that might otherwise force
differentiated cells into S phase. To extend these results,
we analyzed in detail the kinetics of cdk2 activity and the
timing of p21 expression during the process of differentia-
tion. In these experiments, we used a well-characterized
murine skeletal muscle cell line, C2C12 (hereafter referred
to as C2), which can be induced to differentiate in vitro by
serum deprivation (Yaffe and Saxel, 1977). For the analy-
sis of cdk2 activity, immune complexes of cdk2 from lysates
of C2 myoblasts cultured in GM and in DM for different
intervals of time were assayed for associated histone H1
kinase activity. As shown in Fig. 1 A, cdk2-associated ki-
nase activity was detected in lysates of proliferating C2
cells, but not in lysates of C2 cells cultured in DM after 36
or 96 h, a time when myotubes are completely formed
(data not shown). Lysates from these experiments were
also subjected to Western analysis to assess the levels of
p21 protein in proliferating myoblasts and in myoblasts in-
duced to differentiate (Fig. 1 B). C2 myoblasts cultured in
GM displayed low amounts of p21, but after switching to
DM the levels of p21 in these cells increased linearly over
time, peaking at 
 
z
 
36 h, coincidently with the time in which
cdk2 activity is dramatically reduced (Fig. 1 A). Thus, the
loss of cdk2 activity observed during the differentiation of
C2 cells can be attributed, at least in part, to the accumula-
tion of p21, an amount (at least three- to fourfold) which
in the end should suffice to inhibit all cdk2 activity (see be-
low). However, the exact stoichiometry of this interaction
remains to be established. 
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Inactive Cyclin E–cdk2 Complexes Persist in 
Differentiated C2 Cells
 
We next compared the expression levels of cyclin E, cyclin
A, and cdk2 in proliferating myoblasts to that of myoblasts
cultured in DM. Consistent with previous reports (Jahn et
al., 1994; Guo et al., 1995), differentiated muscle cells
showed very little expression if any of cyclin A protein
(data not shown), but only a modest reduction in the ex-
pression of cdk2 (Fig. 2 A). As expected, the expression of
MHC, a specific marker for muscle cell differentiation,
was significantly increased in these cells (Fig. 2 A). Re-
portedly, the level of cyclin E protein does not detectably
change during differentiation (Jahn et al., 1994; Guo et al.,
1995), but we found the amounts of cyclin E in differenti-
ated myotubes compared with that of proliferating myo-
blasts to be significantly lower and of only one form (Fig. 2
A). As such, this form corresponds in size to a previously
reported unphosphorylated form of cyclin E (Koff, 1991;
Koff et al., 1992; Dulic et al., 1992) that is resistant to deg-
radation if assembled into complexes with inactive cdk2
(Clurman et al., 1996). Thus, the cyclin E that we find to
be present in differentiated C2 cells may not only be asso-
ciated with cdk2, but with inhibitory amounts of p21 as
well. As shown in Fig. 2 B, immunoprecipitates of cyclin E
retrieved from extracts of differentiated myotubes do con-
tain cdk2 and p21, and both of these proteins are notice-
ably absent in precipitates obtained with the control anti-
body. Perhaps more importantly, the cyclin E precipitates
recovered from these extracts did not contain the cdk in-
hibitor p27 or the cdk inhibitor p18 (Fig. 2 C). (While this
manuscript was under review, a similar study showing only
the presence of p21 in cyclin E–cdk2 complexes from myo-
tubes was published by Pajalunga et al. [1999]). Taken to-
gether, the results indicate that there are low amounts of
inactive cyclin E–cdk2 complexes in differentiated C2 cells
and that the reason they are nonfunctional is because of
the binding of p21.
 
Purified E1A Restores cdk2-associated Kinase Activity 
in Differentiated Myotubes
 
We recently showed that E1A could restore kinase activity
to cdk2 complexes that have been inactivated by the cdk
inhibitor p27 (Mal et al., 1996), which is closely related to
p21. If E1A could inactivate p21, this could partially ex-
plain the ability of an adenovirus (Crescenzi et al., 1995)
or transiently expressed E1A to force differentiated mus-
cle cells into S phase (see Fig. 6). To explore this possibil-
Figure 1. Inactivation of Cdk2 activity correlates with the timing
of p21 induction during myogenic differentiation. (A) Whole-cell
extracts from C2 cells cultured in GM or in DM at the indicated
times were immunoprecipitated with anti-cdk2 antibodies. Cdk2-
associated kinase activity in the immune complexes was deter-
mined using histone H1 as substrate. (B) Expression of p21 in ex-
tracts used above in A was visualized by immunoblot analysis
using antibodies against p21.
Figure 2. Inactive cyclin E-cdk2-p21 complexes are present in differentiated C2 cells. (A) Levels of cyclin E and cdk2 in C2 cells cultured
in GM or DM for 96 h were determined by immunoblot analysis using antibodies specific for cyclin E or cdk2. C2 cells cultured in DM for
96 h showed .95% of the nuclei to be present in myotubes, and expressed MHC as visualized by immunoblot analysis using antibodies
against MHC. (B) Whole-cell extracts of C2C12 cells cultured in GM or DM for 96 h were immunoprecipitated with antibodies against
cyclin E or nonimmune rabbit IgG. The contents of the precipitated samples were analyzed by immunoblotting using antibodies specific
for cdk2 or p21. (C) Immune complexes of cyclin E, recovered from whole cell extracts of C2 cells cultured in GM or DM for 96 h, were
resolved alongside straight lysate (100 mg) and molecular weight markers on a 12% SDS-polyacrylamide gel and then transferred onto a
polyvinylidene difluoride membrane. Afterwards, the membrane was cut into three strips and separately probed with antibodies specific
for p27, p21, or p18. As control, extracts of C2 cells cultured in GM were separately precipitated with normal rabbit IgG. 
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ity, we first determined whether E1A could in fact restore
kinase activity to cdk2 in differentiated C2 myotubes. We
began by incubating bacterially purified wild-type or mu-
tant E1A proteins in extracts prepared from these cells.
The mixtures, with or without E1A, were then immuno-
precipitated with anti-cdk2, and the resulting immune
complexes were assayed for histone H1 kinase activity. As
before, immune complexes of cdk2 from extracts of differ-
entiated myotubes had very little associated histone H1
activity (Fig. 3 A, lane 2). However, after separately add-
ing wild-type E1A or an E1A mutant (E1A.928) failing to
bind Rb (Wang et al., 1993) to analogous extracts, we
found that immune complexes of cdk2 could now phos-
phorylate histone H1 (Fig. 3 A, lanes 3 and 4) to levels
almost similar to that of cdk2 immune complexes from
proliferating myoblasts. To confirm that extracts from
myotubes contained an inhibitory activity before exposure
to E1A, we mixed this extract with proliferating myoblast
extract (1:1) and found that the kinase activity in associa-
tion with cdk2 complexes was greatly reduced. Moreover,
E1A alone did not inhibit the activity of cdk2 in extracts of
proliferating myoblasts (data not shown). It is noteworthy
that cdk-activating kinase, an enzyme that gives cdks full
kinase activity (Morgan, 1997), was found to be enzymati-
cally active in the extract of differentiated muscle cells
(data not shown). As such, cdk-activating kinase activity is
not regulated by the cell cycle in undifferentiated cells and
cdk activation is therefore controlled by the accessibility of
the substrates (Morgan, 1995). Collectively, we conclude
that inactive cyclin E-cdk2-p21 complexes, which persist in
differentiated C2 cells (Fig. 2 C), retain the potential to un-
dergo a restoration in activity, at least in vitro. However, an
additional effect by E1A on cyclin D3–cdk2 complexes in
association with p21 in extracts of C2 myotubes (Tedesco et
al., 1997; Cenciarelli et al., 1999) cannot be excluded, and
this could also be contributing to the restoration of kinase
activity observed in Fig. 3 A, lanes 3 and 4.
 
E1A Restores Kinase Activity to cdk2 by Targeting an 
Inhibitory Activity, p21
 
Restoration of kinase activity to cdk2 in extracts of differ-
entiated C2 myotubes appeared to correlate to the titrat-
ing out of an inhibitory activity, since cdk2 activity in-
creased linearly after incremental amounts of E1A were
added to fixed amounts of myotube extract (data not
shown). To investigate whether E1A was physically inter-
acting with this inhibitory activity, we incubated E1A in
extracts of myotubes and then recovered it by immunopre-
cipitation with an antibody specific to E1A (M73) (Harlow
et al., 1985). Immune complexes were then treated with
sodium deoxycholate (DOC), which has been previously
proven to release only those proteins that may have asso-
ciated with the respective antigen (Lees et al., 1992; Mal et
al., 1996), in this case E1A. As a negative control, extracts
of myotubes containing E1A in parallel were also immu-
noprecipitated with normal mouse IgG, and likewise, the
resulting immune complexes were disrupted with DOC.
Eluates of both were then separately mixed with extracts
of proliferating myoblasts. After incubation, the mixtures
were immunoprecipitated with an antibody specific for
cdk2, and the ensuing immune complexes assayed for as-
sociated kinase activity using histone H1 as substrate. As
shown in Fig. 3 B, the products released from E1A by M73
contained an inhibitor of cdk2-associated kinase activity
(Fig. 3 B, lane 3), as judged by comparing the activity asso-
ciated with cdk2 from the original extract of proliferating
myoblasts (Fig. 3 B, lane 1). In contrast, products released
from immune complexes derived from E1A containing ex-
tracts with the use of normal mouse IgG had no effect on
cdk2-associated kinase activity (Fig. 3 B, lane 4). Further-
more, the extract to which E1A was added and then re-
moved by M73 had no inhibitory effect on cdk2 activity
when mixed with an extract from proliferating myoblasts
(data not shown). These findings strongly imply that E1A
Figure 3. Purified E1A restores cdk2 activity in differentiated C2
cells. (A) Whole cell extracts of C2 cells cultured in DM for 96 h
with or without the addition of an authentic wild-type E1A (200
ng) or mutant E1A.928 (200 ng) of 243 amino acids were incu-
bated in parallel with whole-cell extracts of proliferating C2 cells
cultured in GM. Cdk2 was then recovered by immunoprecipita-
tion and assayed for associated kinase H1 activity (lanes 1–4).
Lane 5: same assay, except cdk2 activity was determined after
mixing GM extracts (100 mg) with DM extracts (100 mg). (B)
Whole cell extracts were prepared from C2 cells cultured in GM
or in DM for 96 h. Lanes 1 and 2: cdk2-associated histone H1 ki-
nase activity was determined in GM or DM extracts, respectively,
after immunoprecipitation with antibodies against cdk2. Lanes 3
and 4: wild-type E1A (200 ng) was incubated in extracts of DM
and recovered by immunoprecipitation with an antibody specific
for E1A (M73) or normal mouse IgG, respectively. The immune
complexes were treated accordingly (see Materials and Methods)
to release proteins from protein A–Sepharose beads. These prod-
ucts were then mixed with extracts of GM, and afterwards, this
mixture was assayed for cdk2-associated histone H1 kinase activ-
ity after immunoprecipitation. (C) Same experiment as in A ex-
cept this time immune complexes of cdk2 were subject to immu-
noblot analysis and enhanced chemiluminescence, using anti-p21
as a probe. The same membrane was also probed with anti-cdk2,
and this served as a loading control. 
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can directly interfere with an inhibitory activity of cyclin
E–cdk2 in differentiated muscle cells, and because this
complex does not appear to contain p27 or p18, then this
activity is more than likely from p21. With this in mind, we
determined whether E1A could reduce the amount of p21
in association with cyclin E–cdk2 complexes. As before,
the amount of p21 in association with cyclin E–cdk2 com-
plexes from differentiated cells (Fig. 3 C, lane 2) was con-
siderably more than that found in immune complexes of
cdk2 from undifferentiated cells (Fig. 3 C, lane 1). How-
ever, the amount of p21 was greatly reduced in cdk2 im-
mune complexes recovered from extracts of differentiated
cells with the addition of either wild-type E1A or the
E1A.928 mutant (Fig. 3 C, lanes 3 and 4, respectively).
 
E1A and p21 Can Physically Interact with Each Other
 
The implication that E1A was targeting p21 in extracts of
differentiated muscle cells led us to explore whether E1A
could bind directly to this protein, and if so, to what part of
the molecule. By incubating purified E1A with a GST-p21
fusion protein, we were able to determine that E1A could
bind specifically to p21 but not to GST (Fig. 4 A). We
were also able to identify a site on p21 with which E1A in-
teracts by using a set of p21 mutants containing deletions
at the NH
 
2
 
- or COOH-terminal end of the molecule. Cod-
ing sequences for these particular mutants were expressed
as GST fusion proteins, and after purification, each was
separately incubated with purified E1A. The results ob-
tained from these experiments are shown in Fig. 4 A and
schematized in Fig. 4 B. In effect, an NH
 
2
 
-terminal dele-
tion containing amino acid residues 80–164 bound very ef-
ficiently to E1A as did a COOH-terminal deletion con-
taining amino acid residues 1–137 (Fig. 4 A). We conclude
that E1A can directly interact with p21 and that the region
lying between amino acids 80 and 120 of p21 is the major
region responsible for this interaction.
Given that E1A can bind directly to p21, it was equally
important to ascertain the site on E1A to which p21 can
interact. To do so, we challenged GST-p21 fusion proteins
against equal amounts of radioactively labeled E1A mu-
tants generated by an in vitro transcription/translational
system. In analyzing the bound material, we discovered
that an E1A mutant containing a deletion between amino
acids 2–36 (E1A.dl2-36) could not bind to p21 when com-
pared with wild-type or the other E1A mutants (Fig. 4 C).
Figure 4. E1A binds directly
to p21. (A) GST, GST-p21,
or GST-21 deletion mutants,
immobilized on glutathione
beads, were incubated with
purified E1A (75 ng). After
elution of the beads, E1A
was detected by immunoblot
analysis using the anti-E1A
mAb M73. Input refers to
100% of the protein used in
the binding assay. (B) Sche-
matic representation of p21
and p21 deletion mutants, a
summary of their binding ac-
tivity to E1A, and an illustra-
tion of the putative region of
p21 to which E1A may inter-
act. The solid box within the
p21 drawings represent the
binding motifs for cyclin and
cdk2. The binding motif for
PCNA, as well as a second
cyclin binding motif, are
shown as hatched boxes. (C)
[S35]methionine-labeled wild-
type or mutant E1As were
produced by in vitro tran-
scription/translation and then
mixed with GST-p21 or un-
fused GST. Complexes after
glutathione-Sepharose affin-
ity chromatography were an-
alyzed by SDS-polyacryl-
amide gels and fluorography. 
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To be noted is that the E1A.dl2-36 mutant has been previ-
ously characterized in its ability to induce DNA synthesis
in quiescent cells, and although it can still bind Rb, its effi-
ciency in this activity is severely impaired compared with
wild-type E1A (Stein et al., 1990).
 
E1A Expressed in Differentiated Myotubes Associates 
with p21 and Restores Kinase Activity to cdk2
 
Our in vitro results suggest that purified E1A can bind to
and disable the cdk inhibitory activities of p21 when added
to an extract of differentiated muscle cells. The question
that remains, however, is whether E1A can perform these
acts when expressed in differentiated C2 cells. To address
this issue, parallel plates containing the same number of
differentiated C2 myotubes were transfected with plas-
mids encoding either wild-type E1A (pCMV-E1A
 
12S
 
), or
mutant E1A failing to bind Rb (pCMV-E1A.928) or p21
(pCMV-E1A.dl2-36). It is important to note that transfec-
tion occurred under conditions that allowed 
 
z
 
15–20% of
the cells to take up exogenous DNA (Wolff et al., 1992).
After 36 h, transfected myotubes were harvested and ex-
tracts were then prepared accordingly (Mal et al., 1996).
Each of the extracts, in parallel, was immunoprecipitated
for the isolation of cdk2. Immune complexes of cdk2 were
then tested for associated kinase activity using histone H1
as substrate. As shown in Fig. 5 A, plasmids containing ei-
ther wild-type E1A or the E1A mutant failing to bind Rb
(928) increased histone H1 kinase activity to cdk2–cyclin
complexes, whereas the E1A mutant (dl2-36) failing to
bind p21 and the control plasmid did not. As expected, the
cdk2 immune complexes from extracts of proliferating
myoblasts had associated histone H1 kinase activity. The
fact that equivalent expression of the wild-type E1A and
the two E1A mutants were observed in the myotubes after
transfection (Fig. 5 A) strengthens the preceding results.
Incidentally, transient expression of an E1A mutant
(E1A.RG2), which can bind to p21 but not to p300, was
equally efficient as wild-type E1A in restoring cdk2 activ-
ity in myotubes (Mal, A., and M.L. Harter, manuscript in
preparation).
The above-mentioned experiments support the conten-
tion that when E1A is forcibly expressed in myotubes, it
can reactivate cdk2 activity. In this situation, it is quite
probable that E1A may be directly affecting the cdk inhib-
itory activity of p21 since E1A can bind to this protein in
vitro (Fig. 4). This speculation is supported by the fact that
the transcripts and protein levels of p21, p27, and cdk2 re-
main unchanged after E1A is expressed in myotubes (Ti-
ainen et al., 1996; Cenciarelli et al., 1999; Pajalunga et al.,
1999; Mal, A., and M.L. Harter, unpublished results), and
although E1A does increase the level of cyclin E in these
cells (Tiainen et al., 1996b), the elevation of cyclin E alone
does not result in the restoration of cdk2 activity (Pa-
jalunga et al., 1999). For these reasons, we examined
whether a transiently expressed E1A could associate with
p21 in differentiated myotubes. As can be seen in Fig. 5 B,
p21 was present in immune complexes of E1A recovered
from extracts of differentiated myotubes transfected with
the wild-type E1A vector, but not the control vector or the
plasmid encoding the E1A.dl2-36 mutant, which is consis-
tent with our in vitro results.
 
The E1A.dl2-36 Mutant Fails to Induce DNA Synthesis 
in Differentiated Myotubes
 
To determine whether E1A’s ability to restore kinase ac-
tivity to cyclin E–cdk2 complexes in differentiated C2 cells
was of functional importance, we compared wild-type
E1A with mutant E1As for their ability to induce DNA
synthesis in these cells. To reiterate, after proliferating C2
myoblasts develop into multinucleated myotubes (Fig. 6
a), they can no longer synthesize their DNA, not even in
response to serum stimulation (Skapek et al., 1995). How-
ever, DNA replication in myotubes (Fig. 6, b and e) can be
induced after transfection with wild-type E1A or the E1A
mutant (RG2), which can bind Rb and p21 but not p300
(Stein et al., 1990; Chattopadhyay, D., and M.L. Harter,
unpublished data), as judged by the incorporation of the
thymidine analogue BrdU (Fig. 6, d and g) and the stain-
Figure 5. E1A expressed in differentiated C2 cells associates
with p21 and restores kinase activity to cyclin–cdk2 complexes.
(A) C2 cells cultured in DM for 48 h were transfected in parallel
with pCMV-E1A12S, pCMV-E1A.928, pCMV-E1A.dl2-36, or
control plasmid pCMV. After 36 h, cells were collected and
whole cell extracts prepared. Equal fractions of each transfection
(representing protein recovered from the same number of cells)
were analyzed in all experiments. Cdk2-associated kinase histone
H1 activity in transfected myotubes as well as in cells cultured in
GM was determined as for Fig. 3. In the lower panel, extracts of
transfected myotubes were subject to immunoblot analysis and
enhanced chemiluminescence, using anti-E1A as a probe. (B)
The same experiment as in A, except this time immune com-
plexes of E1A were subject to immunoblot analysis and en-
hanced chemiluminescence, using anti-p21 as a probe. 
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ing of E1A (Fig. 6, c and f). More importantly, however,
the E1A.dl2-36 mutant, which fails to bind p21 and restore
kinase activity (Figs. 4 and 5), was incapable of inducing
DNA synthesis in these cells (Fig. 6, h–j). Although the
E1A.928 mutant, which fails to bind Rb, can induce DNA
synthesis in quiescent cells (Flint and Shenk, 1997) albeit
with a much lower efficiency, it was completely ineffective
in inducing DNA replication in myotubes (Fig. 6, k–m),
despite its ability to restore kinase activity to cyclin–cdk2
complexes in these cells (Fig. 5). Nevertheless, this result is
consistent with what has been previously shown with the
use of an E1A.928 adenovirus mutant (Tiainen et al.,
1996b). To be noted is that myotubes transfected with con-
trol plasmid were constantly BrdU-negative, and in paral-
lel experiments, the muscle differentiation marker MHC
was easily detectable (data not shown). Also to be noted is
that some of the nuclei of the BrdU-labeled myotubes that
were transfected with wild-type E1A or the RG2 mutant
appeared to show a doubling in DNA content (Fig. 6, b–g).
Since mitosis in multinucleated myotubes as a result of
adenovirus infection induces the coalescence of formerly
individual nuclei (Crescenzi et al., 1995), this observation
is consistent. A summary of these results and the binding
properties of mutant E1As used in this study are shown in
Table I.
Taken together, these experiments suggests that both
p21 and Rb many be necessary for preventing the reoccur-
rence of DNA replication in differentiated C2 cells.
 
Restoration of Kinase Activity in Differentiated Muscle 
Cells Leads to the Phosphorylation of Rb
 
As in other mammalian systems, hypophosphorylated or
active Rb in proliferating C2 myoblasts becomes phosphor-
ylated when cells enter S phase. Once these cells undergo
differentiation, however, the property of the Rb mole-
cule appears to become permanently confined to a hypo-
phosphorylated state (Lassar et al., 1994). Although the
E1A.928 mutant, which fails to bind Rb, cannot induce
DNA replication in differentiated C2 myotubes (Fig. 6,
Figure 6. E1A mutants fail-
ing to bind p21 or Rb cannot
induce DNA synthesis in dif-
ferentiated muscle cells. C2
cells grown on glass coverslips
and cultured in DM for 72 h
were transfected in parallel
with pCMV-E1A12S, pCMV-
E1A.RG2, pCMV-E1A.dl2-
36, or pCMV-E1A.928. 24 h
later, BrdU was added to the
media and after 12 h, the cul-
tures were fixed (see Materi-
als and Methods) and se-
quentially immunostained for
E1A and incorporated BrdU.
Phase-contrast photomicros-
copy of fixed C2 cells cultured
in DM for 72 h (a) or after
transfection with pCMV-
E1A12S (b), pCMV-E1A.RG2
(e), pCMV-E1A.dl2-36 (h),
or pCMV-E1A.928 (k) is
shown. Myotubes in c and d
and f and g, which correspond
to the same field shown in b
and e, respectively, display
E1A staining (red) and BrdU
incorporation (green). Myo-
tubes in i and l, which corre-
spond to the same fields
shown in h and k, respec-
tively, show E1A staining
but are negative for BrdU (j
and m). 
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h–j), it can restore kinase activity to cyclin E–cdk2 com-
plexes in these cells (Figs. 3 and 5). Given this paradox,
and the importance of phosphorylated Rb in allowing cells
to enter S phase, we examined the phosphorylation state
of Rb in E1A transfected C2 myotubes. As shown previ-
ously (Gu et al., 1993; Thorburn et al., 1993), hyperphos-
phorylated forms of Rb were present in proliferating C2
myoblasts, but only the hypophosphorylated form of Rb
was detectable in the myotubes (Fig. 7, lanes 1 and 2, re-
spectively). However, after these cells were transfected
with wild-type E1A or the E1A.928 mutant, a small
amount of hyperphosphorylated Rb became apparent
(Fig. 7, lanes 3 and 4, respectively), but not in cells that
were transfected with the E1A.dl2-36 mutant (lane 5). The
percentage of hyperphosphorylated Rb found in this ex-
periment was roughly equal to that of the transfection effi-
ciency (15–20%), and the expression of each of the trans-
fected E1As in myotubes was equivalent (Fig. 7, lower
panel), as judged by Western analysis. Thus, although the
expression of wild-type E1A or the E1A.928 mutant in dif-
ferentiated C2 cells are both equally capable of inducing
the phosphorylation of Rb, this in itself is not sufficient for
inducing DNA replication in these cells (Fig. 6).
 
Discussion
 
The regulatory pathways, which are important to main-
taining the silencing of DNA replication in terminally dif-
ferentiated C2 cells, are unique. This is exemplified by the
fact that the exogenous expression of the transcription fac-
tor E2F1, a protein critical for S phase function, cannot
promote these cells, unlike quiescent fibroblasts, into S
phase (Tiainen et al., 1996a). In proliferating C2 myoblasts
as well as in other cell types, it has often been suggested
that E2F1, which activates a number of S phase genes, is
negatively regulated by Rb, and that this is one way in
which Rb inhibits the progression of cells into S phase.
Upon muscle differentiation, the expression of E2F1 dra-
matically decreases (Wang et al., 1995; Puri et al., 1998),
whereas the expression of active or hypophosphorylated
Rb increases (Gu et al., 1993; Thorburn et al., 1993). In
this context, the function of Rb may be other than that of
controlling transcription factors that regulate genes re-
sponsible for the transition into S phase. What this func-
tion might be is still unclear, but studies indicate that
Rb may be playing a critical role in preventing aberrant
DNA synthesis in terminally differentiated muscle cells
(Schneider et al., 1994; Novitch et al., 1996). It is worth
noting, however, that the cdk inhibitor p21, which is in-
duced after myogenesis, may also be important in main-
taining the absence of DNA synthesis in these cells (An-
dres and Walsh, 1996). This work reveals that both Rb and
p21 are necessary for this activity, and demonstrates with
the use of the viral oncoprotein E1A that they cooperate
in maintaining the postmitotic state.
The mechanistic details of what prevents DNA synthesis
from occurring in differentiated muscle cells are poorly
understood. The data available thus far (Fig. 2 A) suggest
that after C2 cells differentiate in culture, they continue to
express low amounts of cyclin E, and this is consistent with
what others have observed in other types of differentiated
cells (Gao and Zelenka, 1997). A majority, if not all, of the
cyclin E molecules were found to be associated with the
cdk2 kinase (Fig. 2 B), but despite this interaction, the cy-
clin E–cdk2 complexes were enzymatically inactive (Fig. 1).
The underlying basis for this inactivity most likely origi-
nates from the cdk inhibitor p21, which had accumulated in
these cells and was shown to be contained in cyclin E im-
mune complexes as apposed to its closely related form p27
(Fig. 2, B and C). Although we were unable to measure the
physiological levels of p21 in the differentiated muscle
cells, we were able to demonstrate a correspondence be-
tween the time p21 is maximally expressed and the time
cdk2 activity becomes inhibited (Fig. 1), an occurrence that
came rather late during the differentiation process.
What role might p21 play in differentiated muscle cells?
Since a single p21 monomer is sufficient to inhibit a cyclin–
cdk2 complex (Hengst et al., 1998), we propose that the
activity of cyclin E–cdk2 complexes in differentiated C2
cells is purposely held in check by the binding of p21. If
true, then perhaps one function of p21 in these cells is to
indirectly prevent the phosphorylation of key regulatory
 
Table I. Binding Properties of E1A Mutants and Their Ability 
to Induce DNA Synthesis in Differentiated Muscle Cells
 
Binding BrdU-positive cells
Mutant p300 Rb p21 C2C12 myotubes
 
wt E1A
 
1
 
*
 
1
 
*
 
1
 
‡
 
1
 
E1A.928
 
1
 
*
 
2
 
*
 
1
 
‡
 
2
 
E1A.RG2
 
2
 
*
 
1
 
*
 
1
 
‡
 
1
 
E1A.dl2-36
 
2
 
*
 
12
 
‡
 
2
 
1
 
, positive for binding to a cellular protein; 
 
2
 
, negative for binding to a cellular protein.
*Data obtained from the work of Stein et al. (1990) and Wang et al. (1993).
 
‡
 
Work described herein, and unpublished results (Chattopadhyay, D., and M.L. Harter).
Figure 7. Restoration of kinase activity in differentiated C2 cells
leads to the phosphorylation of Rb. Transfection of C2 myotubes
(DM) and the preparation of whole cell extract is described for
Fig. 5. These extracts were electrophoresed alongside whole cell
extracts of C2 myoblasts (GM), transferred to polyvinylidene diflu-
oride membrane, and probed with an Rb-specific polyclonal anti-
body followed by enhanced chemiluminescence detection. In the
lower panel, the same extracts were subject to immunoblot analy-
sis and enhanced chemiluminescence, using anti-E1A as probe. 
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proteins (see below) that are temporally important to the
initiation of DNA synthesis. This contention is supported
by the fact that when p21 is inactivated in differentiated
C2 cells, a key member of the mini chromosome mainte-
nance (MCM) family of proteins becomes phosphory-
lated (Mal, A., and M.L. Harter, manuscript in prepara-
tion). The MCM proteins are known components of
prereplication complexes (pre-RCs), and current models
suggest that they make nuclei competent for DNA replica-
tion (Dutta and Bell, 1997).
The striking restoration of cdk2 activity in extracts of
differentiated C2 cells after the addition of purified E1A
(Fig. 3 A), and the fact that a wild-type E1A or an E1A
mutant failing to bind Rb can efficiently release p21 from
cyclin E–cdk2 complexes (Fig. 3, B and C), supports the
notion that p21 is taking an active role in arresting the ac-
tivity of this kinase in vivo. The removal of p21 from these
complexes most likely correlates with E1A’s ability to
bind directly to p21 (Fig. 4 C). This finding is consistent
with E1A’s capacity to directly associate with the cdk in-
hibitor p27, a family member of p21 (Mal et al., 1996; No-
mura et al., 1998; Orend et al., 1998). The fact that NH
 
2
 
-
terminal residues, specifically amino acids 2–36, appear to
be critical to the binding of p21 (Fig. 4 C) is not too sur-
prising, since most of the cellular proteins (e.g., p300 and
Rb) known to interact with E1A bind to subregions within
the NH
 
2
 
 terminus of this protein (Stein et al., 1990).
We have also demonstrated the sequences required for
p21 and E1A binding, and find that the E1A binding site
of p21 does not appear to include either of the two cyclin
or cdk domains or the proliferating cell nuclear antigen
(PCNA) domain (Fig. 4, A and B). Instead, the sequences
that appear to be responsible for binding E1A are located
between amino acids 80–120. It is interesting to note, how-
ever, that this particular region of p21 is distinct from that
which binds the human papillomavirus E7 oncoprotein
(Funk et al., 1997), which has been recently shown to as-
sociate with p21 and abrogate its ability to inhibit cyclin
E–cdk2 complexes during keratinocyte differentiation
(Funk et al., 1997; Jones et al., 1997). Indeed, the E7 binding
site of p21 seems to be displaced toward the COOH-termi-
nal end and overlaps with the PCNA binding domain. The
reason the sequences in p21 that bind E1A or E7 are dis-
tinctly different is not presently understood. However, it
should be noted that apart from preventing p21 from in-
hibiting cyclin E–cdk2 complexes, E7 also has the ability
to neutralize p21’s activity in inhibiting PCNA-dependent
DNA replication (Funk et al., 1997). Furthermore, unlike
the p21 binding site of E1A, which maps upstream (be-
tween amino acids 2–36) of the Rb binding site (Fig. 4 C),
the p21 binding site of E7 appears to include sequences
that are responsible for the binding of Rb (Jones et al.,
1997). Thus, although both E1A and E7 can abrogate the
inhibitory activities of p21, it appears that they may have
evolved different ways of doing so.
The discovery that the viral oncoproteins E1A or simian
virus 40 large T could overcome the proliferative block of
terminally differentiated C2 cells by reactivating authentic
DNA synthesis (Crescenzi et al., 1995; Endo and Nadal-
Ginard, 1989) was significant, since it suggested that these
cells had retained the potential to undergo a complete
and well-orchestrated S phase. As such, the unlocking of
pathways to DNA replication in differentiated muscle cells
cannot be achieved by mitogenic signaling (Lassar et al.,
1994) but can by the simple expression of E1A or simian
virus 40 large T. Indeed, that these two proteins alone can
induce DNA synthesis in differentiated C2 cells suggests,
at the very least, that components (ORC, Cdc6, MCMs) of
pre-RCs are still being expressed in these cells. If true,
then maintaining their assembly at origins of DNA repli-
cation and inactivity in DNA synthesis would require an
absence of cdk activity, and possibly the functioning of
other proteins as well (Dutta and Bell, 1997). Normally,
pre-RCs require the activation of cdk2 activity to induce
DNA synthesis in mammalian systems (Dutta and Bell,
1997). Thus, if E1A were to switch on cyclin E–cdk2 activ-
ity in differentiated muscle cells by interfering with p21’s
activity, then this could be one way in which E1A is able
force these cells into S phase. In support of this model, our
data suggest that E1A or E1A mutants failing to bind Rb
or p300 (data not shown) can efficiently restore activity to
cdk2 complexes in differentiated C2 cells, whereas the
E1A mutant (dl2-36) failing to bind p21 cannot (Fig. 5 A).
Moreover, with the exception of E1A.dl2-36, wild-type
E1A and the other E1A mutants are equally efficient in
reducing the amount of p21 in association with cdk2 com-
plexes, both in vitro (Fig. 3) and in vivo (Mal, A., and M.L.
Harter, manuscript in preparation), and we suspect that
this correlates with their ability to interact with p21 when
expressed in myotubes (Fig. 5 B). Finally, although we be-
lieve, but as yet cannot prove, that components, or at least
parts thereof, of pre-RCs are being constitutively pro-
duced in differentiated C2 cells, we cannot rule out the
possibility that some of these factors may in fact be in-
duced once E1A is expressed in these cells.
Regulatory cascades control the initiation of muscle cell
differentiation, and the players considered to be most im-
portant to this process are MyoD, p21, and Rb. For exam-
ple, in response to differentiation signals, the transcrip-
tional factor MyoD, which is primarily responsible for
initiating the myogenic program, upregulates p21, which in
turn inhibits cdk activity, causing cells to irreversibly arrest
in G1 and maintain Rb in an active or hypophosphory-
lated state (Lassar et al., 1994). In vitro studies have shown
that Rb can bind directly to MyoD, and this has led others
to postulate that Rb is totally required for the withdrawal
of muscle cells from the cell cycle (Gu et al., 1993). This
notion, however, is challenged by the fact that Rb-defi-
cient fibroblasts can still exit the cell cycle and undergo
differentiation after MyoD is ectopically expressed in
these cells (Novitch et al., 1996). Moreover, ectopic ex-
pression of cyclin D1 can inhibit muscle cell differentiation
independently of Rb hyperphosphorylation (Skapek et al.,
1995). Thus, although Rb’s role in the early stages of myo-
genesis appears to be comparatively obscure, its activity in
regulating or maintaining the postmitotic state of differen-
tiated muscle cells is, perhaps, a little more definitive. For
example, despite the fact that Rb-deficient myocytes can
successfully differentiate into myotubes, they do not ap-
pear permanently withdrawn from the cell cycle, since
DNA replication can occur in these cells upon mitogenic
stimulation (Schneider et al., 1994; Novitch et al., 1996;
Wang and Walsh, 1996). Furthermore, myotubes in the ab-
sence of Rb also display a higher frequency of apoptosis 
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(Wang et al., 1997), perhaps because of endoreduplication,
since nuclei in the back muscles of Rb
 
2
 
/
 
2
 
 fetuses show a
DNA content of 
 
.
 
2 N (Zacksenhaus et al., 1996). Such re-
sults forces one to reinterpret Rb’s role in differentiated
muscle cells, and instead of binding to or repressing E2F as
it does when restraining the G1–S transition in proliferat-
ing myoblasts, Rb may be targeting or affecting proteins
that are mainly involved in the temporal aspect of DNA
replication. Indeed, it is interesting that an active Rb mu-
tant devoid of phosphorylation sites can interfere with
DNA synthesis in S phase–committed cells (Knudsen et
al., 1998) and that pRb can bind directly to the DNA li-
censing factor MCM7 (Sterner et al., 1998).
Our observations further substantiate Rb’s importance
in assuring that DNA synthesis does not occur in differen-
tiated C2 cells; however, critical issues remain. Although
we can conclude that wild-type E1A and an E1A mutant
(RG2) failing to bind p300 are both very efficient in induc-
ing DNA synthesis in differentiated C2 cells, the E1A.dl2-
36 mutant, which fails to bind p21, cannot, despite the fact
that it can still bind Rb (Fig. 6). A second issue is that the
E1A.928 mutant, which can no longer bind to Rb, is also
defective in inducing DNA synthesis in these cells (Fig. 6),
even though it can bind to p21 and restore kinase activity
to cdk2 (Figs. 3, 4, and 5). In addition, this mutant can also
induce the phosphorylation of Rb, whereas the dl2-36 mu-
tant cannot (Fig. 7). Although there are 16 bona fide sites
on Rb that can be potentially phosphorylated by cdks
(Dyson, 1998), the phosphorylated form of Rb that is gen-
erated in this case is inadequate in allowing the reinitiation
of DNA synthesis in differentiated C2 cells. This result is
consistent with previous findings, which suggest that Rb’s
activities may be controlled in part by the site(s) at which
Rb is phosphorylated (Knudsen and Wang, 1996). Given
this set of circumstances, we speculate that the activation of
cdk activity and the loss of Rb function are both necessary
requirements to reinitiate DNA replication in differentiated
muscle cells. We also postulate that Rb is functioning down-
stream of p21, and possibly other cdk inhibitors as well, to
maintain the absence of DNA synthesis in these cells.
Finally, it would appear that one of the purposes for p21
in differentiated muscle cells is to prevent the escape of
cdk activity so as to neither activate nor indirectly induce
the components of pre-RCs, which might lead to inappro-
priate DNA synthesis in these cells. However, the purpose
of a functionally active Rb protein in differentiated muscle
cells has yet to be defined. Although Rb is best known for
its role in repressing E2F1-mediated transcription, these
cells have very little if any E2F1 expression. Although this
in itself does not rule out the possibility that Rb may still
be acting as a negative regulator of transcription, it does
leave us with the prospect that Rb may be directly or indi-
rectly targeting factors, which could be networking be-
tween DNA replication and transcriptional processes.
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